Report 2020, CampusPharma AB, Norway												
Published: 2021-04												
	Full name HCPs: City of Principal Practice HCOs: city of practice (registered address) Country of principal practice			Principal practice address (e.g. clinic/ office/ healthcare unit/department) Unique identifier OPTIONAL		Donations to HCOs (article 9)	Contribution to costs of events (article 9)			Fee for service and consultancy (article 9)		TOTAL O <i>PTIONAL</i>
	(article 2)	(article 9)	(article 1)	(article 9)	(article 9)		Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an event	Registration fees	Travel and accommodation	Fees (Euro)	Related expenses agreed in the fee for service or consultancy contract, including travel and	
INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authoritie consultation only, as appropriate.												thorities'
		ensfers during 2	2020			N/A	N/A	N/A	N/A			
	OTHER, not included above - where information cannot be disclosed on an individual basis with regard to GDPR.											
	Aggregate amount attributable to transfers of value to such Recipients - article 10 Number of Recipients						N/A	N/A	N/A	Aggregate	Aggregate	
							N/A	N/A	N/A	Amount	Amount	
	% of total number of reci	N/A	N/A	N/A	N/A	%	%	N/A				
	appropriate)	line per HCO (i.e. all tr ransfers during		luring a year for an indi	ividual HCO will b	e summed up	: itemization shoul	d be available f	or the individual Rec	ipient or public au	thorities' consulta	tion only, as
	OTHER, not included above - where information cannot be disclosed per HCO for legal resons.											
	Aggregate amount attributable to transfers of value to such Recipients - article 10 Number of Recipients					N/A	N/A	N/A	N/A			
						N/A	N/A	N/A	N/A			
	% of total number of reci	ipients of individual HC	Os - article 10			N/A	N/A	N/A	N/A			N/A
	Not: N/A = Not Applicable											
	AGGREGATE DISCLOSURE											
R&D	Transfers of value re Research & Development (as defined) (article 12 and article 1)											